NOS1 and cardiovascular disorder: Direct modulation of NOS activity through isoform-specific inhibitors or enhancers, such as iNOS inhibitors and eNOS activators, has shown efficacy in preclinical models of inflammation, cardiovascular diseases, and neurodegeneration.